Loading organizations...
§ Private Profile · Geneva, Switzerland
Medical device company developing devices for catheter ablation in cardiac electrophysiology, focused on contact-force measurement.
Founded in 2003, Endosense is a Geneva, Switzerland-based medical technology company developing contact-force measurement devices to improve the safety and efficacy of catheter ablation procedures for treating cardiac arrhythmias. The organization pioneered this field through its TactiCath system, which provides hospital physicians with real-time contact force data during complex electrophysiology treatments. Led by executives Jan Keltjens and Eric Le Royer, the enterprise secured substantial venture capital backing, including a $36 million Series B round led by Edmond de Rothschild Investment Partners and a $40.3 million Series C financing led by NGN Capital. Other notable institutional investors in the medical device manufacturer included NeoMed Management and Sectoral Asset Management, helping the business generate revenue from European sales of its flagship catheter. The business was acquired by St. Jude Medical in 2013 for a total consideration of up to $331 million.
Endosense has raised $150.6M across 5 funding rounds.
Endosense has raised $150.6M in total across 5 funding rounds.
Endosense SA was a medical technology company that developed the TactiCath, a force-sensing ablation catheter providing real-time contact force measurement to improve the efficacy, safety, and reproducibility of catheter ablation procedures for treating cardiac arrhythmias.[1][2][3] It served electrophysiologists and cardiac specialists addressing irregular heartbeats, solving challenges in ablation precision that reduced procedure success rates and increased risks like complications from inadequate tissue contact.[1][3] Founded in 2003, the company raised $100.6M before being acquired by St. Jude Medical, marking strong growth in the electrophysiology market.[1][3]
Note: A separate, newer entity at endosense.org focuses on at-home rapid tests for endometriosis using multiplexed lateral flow assays for protein and microRNA biomarkers, offering results in under 20 minutes for $30 to cut diagnostic delays and costs compared to invasive laparoscopy.[4] This profile centers on the acquired cardiac firm due to query alignment with historical tech records, but the diagnostics startup represents an emerging player in women's health.
Endosense SA was founded in 2003 in Geneva, Switzerland, as a medtech innovator targeting cardiac arrhythmias.[2][3] Backed by investors including Edmond de Rothschild Investment Partners, NeoMed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners, Initiative Capital Romandie, and NGN Capital, it pioneered contact-force measurement in ablation with proprietary Touch+ sensor technology.[2][3] Key milestones included the TactiCath launch, positive 12-month TOCCATA study data in 2010 confirming clinical benefits, and completion of the U.S. TOCCASTAR IDE trial by 2013, paving the way for FDA submission.[2][3] The company was acquired by St. Jude Medical, enhancing its atrial fibrillation portfolio and accelerating U.S. market entry.[3]
Endosense rode the early 2000s surge in catheter ablation for atrial fibrillation, a growing epidemic driven by aging populations and rising arrhythmia prevalence, where imprecise contact led to suboptimal outcomes.[1][3] Timing was ideal amid electrophysiology market expansion, with force-sensing addressing a critical gap in real-time feedback, influencing standards for safer minimally invasive cardiac interventions.[2][3] Its acquisition by St. Jude Medical integrated the tech into broader EP ecosystems, spurring innovations like AI-enhanced mapping and setting precedents for sensor-driven medtech that competitors like AutoGenomics or Seno Medical later emulated in diagnostics.[1][3]
Post-2013 acquisition, Endosense's TactiCath tech evolved within Abbott (via St. Jude legacy), likely fueling ongoing EP advancements amid rising AFib cases and ablation demand projected to grow with AI and robotics.[3] Trends like personalized cardiac care and minimally invasive devices will shape its legacy, amplifying influence in global arrhythmia management. Meanwhile, the newer EndoSense diagnostics startup could disrupt endometriosis care by scaling affordable at-home testing, tying back to medtech's shift toward accessible, patient-centric solutions that Endosense SA exemplified in cardiac innovation.[4]
Endosense has raised $150.6M in total across 5 funding rounds.
Endosense's investors include 3i, NeoMed Management, Andera Partners.
Endosense has raised $150.6M across 5 funding rounds. Most recently, it raised $29.4M Other Equity in November 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 21, 2024 | $29.4M Venture Round | 3I, Neomed Management | — | Announced |
| Nov 1, 2013 | $41M Series C | — | Andera Partners | Announced |
| Mar 5, 2013 | $4.2M Series C Plus | — | — | Announced |
| Nov 1, 2012 | $40M Series C | — | Andera Partners | Announced |
| Oct 1, 2009 | $36M Series B | — | Andera Partners | Announced |